{"ticker": {"uuid": "aff91a92-f349-4f02-b09d-27e5b52da83e", "symbol": "XERS", "name": "Xeris Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Enterprise value to revenue forward of Xeris Biopharma Holdings, Inc. \u2013 NASDAQ:XERS", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNNUZYWExTSkRocHUwSFpQbHpYVXFOSzNwM0lPWkZzcEdxUEpYYW9UQlN5SWRHbHZQYWZGVXdrQUxNWVg4M1lBcG1tX0plRFlhT0kxSkZGNmJOUlZFaVRjMmo5MjZkajJoQWtSRlluaTR5Z3pZNTdHQ2NKcnh5NGpLRldvWndldU5GeVFFajdZWklQR1diM3czMHR6VWl6YWlSWHY4VnltenNHNFlT?oc=5", "source_name": "TradingView", "published_at": "2026-07-10T12:39:28+00:00", "published_display": "10 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma (XERS) Moves 6.8% Higher: Will This Strength Last?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPMG9rc0hLS0RtQUxQaGVDRHJqeUdnZ1kybXlkMXk2dmFILW5TVzJmWUxvOF8tZ3ZKTFFFMC1yRzJjYUhNRlA2Z3VGNjNMcm5GSkd0T3A2M2o0VnlmS2ZlTHFuUy1oSS0yRm5qSW5RZUpSUHJtTmJldnIzOW42ZVR3dWFfNlFyeE5KaHg2YThLYnM3SEhuRVNwbA?oc=5", "source_name": "Market source", "published_at": "2026-07-08T14:37:00+00:00", "published_display": "08 Jul 2026 14:37", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma CFO Steven Pieper sells $383,176 in company stock", "summary": "Xeris Biopharma's CFO, Steven Pieper, sold 45,000 shares of company stock for approximately $383,176 in early July through a pre-arranged trading plan. This sale occurred after the stock delivered a 78% return over the past year, and InvestingPro data suggests the stock is curren", "url": "https://www.investing.com/news/insider-trading-news/xeris-biopharma-cfo-steven-pieper-sells-383176-in-company-stock-93CH-4780301", "source_name": "Investing.com", "published_at": "2026-07-08T11:11:28", "published_display": "08 Jul 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Xeris Biopharma Holdings, Inc. \u2013 NASDAQ:XERS", "summary": "The article focuses on the \"Price to earnings forward\" metric for Xeris Biopharma Holdings, Inc. (NASDAQ: XERS). It appears to be a financial data page from TradingView, providing an overview of the company's financials for investors and analysts interested in its valuation.", "url": "https://www.tradingview.com/symbols/NASDAQ-XERS/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T02:09:45", "published_display": "08 Jul 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma Holdings Insider Sold Shares Worth $383,176, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/xeris-biopharma-holdings-insider-sold-211904969.html", "source_name": "MT Newswires", "published_at": "2026-07-07T21:19:04+00:00", "published_display": "07 Jul 2026 21:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma CFO Steven Pieper sells $383,176 in company stock By Investing.com", "summary": "Steven Pieper, the CFO of Xeris Biopharma Holdings Inc. (NASDAQ:XERS), sold a total of 45,000 shares of company stock for approximately $383,176 in early July, under a pre-arranged trading plan. This sale follows a strong 78% return for the stock over the past year. After these t", "url": "https://ca.investing.com/news/stock-market-news/xeris-biopharma-cfo-steven-pieper-sells-383176-in-company-stock-93CH-4724053", "source_name": "Investing.com Canada", "published_at": "2026-07-07T21:41:51", "published_display": "07 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Xeris Pharmaceuticals Inc For: 7 July By Investing.com", "summary": "This article reports on a Form 4 filing for Xeris Pharmaceuticals Inc. on July 7, 2026. Form 4s are SEC filings used to report changes in beneficial ownership of a company's stock by insiders. The article indicates that Xeris Pharmaceuticals Inc. (XERS) stock was up 6.93% at the ", "url": "https://ca.investing.com/news/stock-market-news/form-4-xeris-pharmaceuticals-inc-for-7-july-93CH-4724061", "source_name": "Investing.com Canada", "published_at": "2026-07-07T21:41:51", "published_display": "07 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 XERIS BIOPHARMA HOLDINGS For: 7 July By Investing.com", "summary": "Investing.com reports the filing of Form 144 for Xeris Biopharma Holdings (XERS) on July 7. The article provides the company's stock performance and states that the information is \u00a9 Reuters. This brief notice is part of a larger financial news update.", "url": "https://ca.investing.com/news/stock-market-news/form-144-xeris-biopharma-holdings-for-7-july-93CH-4723968", "source_name": "Investing.com Canada", "published_at": "2026-07-07T20:41:51", "published_display": "07 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Steven Pieper sells 17,400 shares for $147,900 \u2014 XERS", "summary": "A recent SEC Form 144 filing indicates that Steven Pieper sold 17,400 shares of Xeris Biopharma Holdings, Inc. (XERS) common stock for a total of $147,900 on July 6, 2026. This transaction was executed under a 10b5-1 trading plan. The filing also notes prior issuer transactions f", "url": "https://www.stocktitan.net/sec-filings/XERS/144-xeris-biopharma-holdings-inc-sec-filing-bacc152115a4.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:41:51", "published_display": "07 Jul 2026 20:41", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma (XERS) officer sells 45,000 shares under Rule 10b5-1 plan", "summary": "Steven Pieper, an officer at Xeris Biopharma Holdings (XERS), sold 45,000 shares of common stock over two days, July 6-7, 2026, for a total of $383,176. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted in August 2025. After these transactions, Piep", "url": "https://www.stocktitan.net/sec-filings/XERS/form-4-xeris-biopharma-holdings-inc-insider-trading-activity-02ed52e75229.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:41:51", "published_display": "07 Jul 2026 20:41", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Xeris Biopharma Holdings, Inc. \u2013 NASDAQ:XERS", "summary": "This article provides financial data for Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), specifically focusing on its enterprise value to EBITDA forward metric. It appears to be a stub or data-focused page from TradingView, indicating that the market was closed at the time of acce", "url": "https://www.tradingview.com/symbols/NASDAQ-XERS/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T23:39:38", "published_display": "06 Jul 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider reports 400-share purchase and 17,000 RSUs | XERS SEC Filing - Form 144", "summary": "A recent SEC Form 144 filing for Xeris Biopharma Holdings, Inc. (XERS) reported insider transactions, including an open-market purchase of 400 common shares on May 17, 2017, and an issuance of 17,000 restricted stock units (RSUs) on December 28, 2017. The filing's header date is ", "url": "https://www.stocktitan.net/sec-filings/XERS/144-xeris-biopharma-holdings-inc-sec-filing-092e27d983d3.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:11:20", "published_display": "06 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Xeris Biopharma Holdings, Inc. \u2013 NASDAQ:XERS", "summary": "This article provides financial data for Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), specifically focusing on its enterprise value to EBIT forward. It indicates market details such as \"Market closed\" and \"No trades,\" suggesting the data presented might be static or from a non-", "url": "https://www.tradingview.com/symbols/NASDAQ-XERS/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T17:11:20", "published_display": "06 Jul 2026 17:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Xeris Biopharma Holdings, Inc. \u2013 NASDAQ:XERS", "summary": "This article provides the \"Price to book forward\" for Xeris Biopharma Holdings, Inc. (NASDAQ: XERS). It is a financial data point displayed within the TradingView platform, showing the value and change percentage for a specific period. The content is primarily a presentation of t", "url": "https://www.tradingview.com/symbols/NASDAQ-XERS/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T20:09:55", "published_display": "05 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Xeris Biopharma (XERS) Is Up 7.7% After Governance, IP, And Balance Sheet Moves - And What's Next", "summary": "Xeris Biopharma (XERS) recently saw a 7.7% increase following several strategic moves including governance changes, intellectual property advancements, and balance sheet improvements. These actions, such as appointing a new Board Chair, securing a Keveyis patent extension until 2", "url": "https://www.sahmcapital.com/news/content/why-xeris-biopharma-xers-is-up-77-after-governance-ip-and-balance-sheet-moves-and-whats-next-2026-07-05", "source_name": "Sahm", "published_at": "2026-07-05T11:11:28", "published_display": "05 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Xeris Biopharma Holdings, Inc. \u2013 LSE:0A8E", "summary": "This article provides limited financial data for Xeris Biopharma Holdings, Inc. (LSE:0A8E), specifically its \"Price to book forward\" metric. The content primarily focuses on the company's financial overview within the TradingView platform and includes extensive navigation and cop", "url": "https://www.tradingview.com/symbols/LSE-0A8E/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T01:41:22", "published_display": "05 Jul 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Xeris Biopharma Holdings, Inc. \u2013 NASDAQ:XERS", "summary": "This article provides financial information for Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), specifically focusing on its forward price to sales ratio. The content is presented within the TradingView platform, offering various market analysis tools and data provided by ICE Data", "url": "https://www.tradingview.com/symbols/NASDAQ-XERS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T12:40:13", "published_display": "04 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Xeris Biopharma Holdings (XERS)", "summary": "This article analyzes the historical performance of investing $1,000 in Xeris Biopharma Holdings (XERS) over various periods, showing significant returns for investments made one and five years ago, but a loss for investments since its 2018 trading start. It details the company's", "url": "https://www.stocktitan.net/tools/stock-return-calculator/XERS", "source_name": "Stock Titan", "published_at": "2026-07-04T09:41:22", "published_display": "04 Jul 2026 09:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma Holdings (XERS) Patent Win Puts Its Valuation Back In Focus", "summary": "Xeris Biopharma Holdings (XERS) has garnered attention due to a patent win for its Keveyis product, potentially extending protection until 2039, and recent board and leadership changes. Despite being considered 25.7% undervalued at its current price of $8.28 against a fair value ", "url": "https://www.sahmcapital.com/news/content/xeris-biopharma-holdings-xers-patent-win-puts-its-valuation-back-in-focus-2026-07-03", "source_name": "Sahm", "published_at": "2026-07-03T10:10:26", "published_display": "03 Jul 2026 10:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)", "summary": "Xeris Biopharma Holdings, Inc. announced that its Compensation Committee granted non-qualified stock options and restricted stock units for an aggregate of 221,323 shares to 47 new employees. These inducement grants are made under Nasdaq Listing Rule 5635(c)(4) and are intended t", "url": "https://www.businesswire.com/news/home/20260702095916/en/CORRECTING-and-REPLACING-Xeris-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635C4", "source_name": "Business Wire", "published_at": "2026-07-03T02:41:24", "published_display": "03 Jul 2026 02:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beth Hecht Sells 16,666 Shares of Xeris Biopharma Holdings Inc (XERS)", "summary": "Beth Hecht, an insider at Xeris Biopharma Holdings Inc (XERS), sold 16,666 shares of the company on July 1, 2026, bringing her total ownership to 1,161,128 shares. This sale contributes to a pattern of 24 insider sells and no buys over the past year. The stock, trading at $8.03, ", "url": "https://www.gurufocus.com/news/8943773/beth-hecht-sells-16666-shares-of-xeris-biopharma-holdings-inc-xers", "source_name": "GuruFocus", "published_at": "2026-07-02T23:41:24", "published_display": "02 Jul 2026 23:41", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Xeris Pharmaceuticals Inc For: 2 July By Investing.com", "summary": "The article reports on a Form 4 filing for Xeris Pharmaceuticals Inc. on July 2. Form 4 filings detail changes in beneficial ownership of company securities by insiders. The article also provides various financial market data and news headlines.", "url": "https://ca.investing.com/news/stock-market-news/form-4-xeris-pharmaceuticals-inc-for-2-july-93CH-4719284", "source_name": "Investing.com Canada", "published_at": "2026-07-02T22:41:24", "published_display": "02 Jul 2026 22:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma (XERS) director Nerissa Kreher listed as reporting person on Form 3", "summary": "Xeris Biopharma Holdings, Inc. director Nerissa Kreher has been listed as a reporting person on a recently filed Form 3. This initial statement of beneficial ownership indicates no reported buying, selling, acquiring, disposing, or other share transactions, with all transaction c", "url": "https://www.stocktitan.net/sec-filings/XERS/form-3-xeris-biopharma-holdings-inc-initial-statement-of-beneficial-o-0cbc35804beb.html", "source_name": "Stock Titan", "published_at": "2026-07-02T22:09:36", "published_display": "02 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Xeris Biopharma (NASDAQ: XERS) receives stock and options grants", "summary": "Xeris Biopharma director Nerissa Kreher received equity-based compensation including 33,582 restricted stock units and stock options for 37,910 shares with an exercise price of $8.00. Both grants vest over three years, contingent on her continued service on the board. This Form 4", "url": "https://www.stocktitan.net/sec-filings/XERS/form-4-xeris-biopharma-holdings-inc-insider-trading-activity-3fef34ee64c4.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:41:24", "published_display": "02 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Planned sale: Xeris Biopharma (XERS) officer trades 16,666 shares", "summary": "Xeris Biopharma Holdings, Inc. officer Beth Hecht reported selling 16,666 shares of common stock at a weighted average price of $8.0319 per share. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 8, 2025. After the sale, Hecht retains ", "url": "https://www.stocktitan.net/sec-filings/XERS/form-4-xeris-biopharma-holdings-inc-insider-trading-activity-46469f0eb976.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:41:24", "published_display": "02 Jul 2026 21:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)", "summary": "Xeris Biopharma Holdings, Inc. announced that its Compensation Committee granted restricted stock units for 221,323 shares of common stock to 47 new employees on July 1, 2026. These grants were made under Xeris' Inducement Equity Plan, exclusively for new hires to incentivize emp", "url": "https://sg.finance.yahoo.com/news/xeris-announces-inducement-grants-under-200500769.html", "source_name": "Market source", "published_at": "2026-07-02T20:05:17", "published_display": "02 Jul 2026 20:05", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris gives 47 new hires 221,323 stock awards under Nasdaq rule", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPM19iTDVucnh5b1dqSXhkS2dlMzRUSDFaRUlnd2Nqa0M2SHR1QXVqSTdVUmh3NGc5a2RZMnhTRUFkMEVhWHhfcmViMVBZV1k5TDhQdXdRemlHTS14MXNhQkVUQU9GdXNVaWFTeDNmR0JZQm9WZEpUVDJMemZRRmd2T2dZYXoxbFNzenA5a2xncHNPSkZvVXk3dGloSEJldWc4MFdTTTRGQ29WNU40a3hRSVQtdGVQX0haakJLMW5n?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma (XERS) officer sells 90,000 shares under 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQUi00RGVaRGJKLU9QZ0RkMjBxYkdtSEFkd0t5RTE5SnE0TFctQ0lRZjhsRzBvQ1NQeWNfQnBzRENYanpUWGhDOUhCR05iQXFpS3FOLXFEREJQTE8zd014MHpRV1cwOXF1djA4YzJKcnktM2FpU3cxTGE3aVlVc2VFM25yWURBVjZyaTRuNG5wN1NHajV4QkQybWdtUXdLcmFaV2szQjZXaFh2UmtXSkYtSmlHd2g1UVNXSXpLWm1Dbw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Xeris Biopharma Holdings, Inc. SEC Filing", "summary": "This article reports on a Form 144 SEC filing by Xeris Biopharma Holdings, Inc. (XERS), indicating an intent to sell 120,000 shares of common stock with an aggregate market value of $950,400.00. The securities were acquired on January 29, 2024, as Restricted Stock Units from the ", "url": "https://www.stocktitan.net/sec-filings/XERS/144-xeris-biopharma-holdings-inc-sec-filing-27b9d312441a.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:41:17", "published_display": "01 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XERS - Xeris Biopharma Holdings Inc Options", "summary": "This page provides an extensive overview of Xeris Biopharma Holdings Inc (XERS), including its last closing price, financial metrics, valuation ratios, and performance indicators. It also lists key statistics like market capitalization, income, sales, EPS, insider ownership, inst", "url": "https://finviz.com/stock?t=XERS&ty=oc&ta=0&p=d", "source_name": "Finviz", "published_at": "2026-07-01T12:39:24", "published_display": "01 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma (NASDAQ: XERS) adds Nerissa Kreher and reshapes board", "summary": "Xeris Biopharma has announced significant changes to its Board of Directors, effective July 1, 2026. The company expanded its board from seven to eight members with the appointment of Dr. Nerissa Kreher as a Class III director. Additionally, CEO John Shannon has been named Chairp", "url": "https://www.stocktitan.net/sec-filings/XERS/8-k-xeris-biopharma-holdings-inc-reports-material-event-07d4a8f73da8.html", "source_name": "Stock Titan", "published_at": "2026-06-30T20:09:28", "published_display": "30 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris CEO picks up chairman role at fast-growing biopharma", "summary": "John Shannon, the CEO of Xeris Biopharma, has been appointed chairman of the company. This move sees him taking on an expanded leadership role at the fast-growing biopharma firm. The article, however, does not provide further details on the implications of this new appointment or", "url": "https://www.chicagobusiness.com/health-care/ccb-shannon-xeris-chairman-20260630/", "source_name": "Crain's Chicago Business", "published_at": "2026-06-30T17:40:25", "published_display": "30 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma Holdings, Inc. Announces Board Changes, Effective July 1, 2026", "summary": "Xeris Biopharma Holdings, Inc. announced significant changes to its Board of Directors, effective July 1, 2026. John Shannon, the current Chief Executive Officer, will also assume the role of Chair of the Board, succeeding Marla Persky who remains as Lead Independent Director. Ad", "url": "https://www.marketscreener.com/news/xeris-biopharma-holdings-inc-announces-board-changes-effective-july-1-2026-ce7f5fdcdf89f02d", "source_name": "www.marketscreener.com", "published_at": "2026-06-30T13:40:25", "published_display": "30 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma Appoints CEO John Shannon Board Chair", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/xeris-biopharma-appoints-ceo-john-114842950.html", "source_name": "MT Newswires", "published_at": "2026-06-30T11:48:42+00:00", "published_display": "30 Jun 2026 11:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Announces Updates to Its Board of Directors", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/xeris-announces-updates-board-directors-110000958.html", "source_name": "Business Wire", "published_at": "2026-06-30T11:00:00+00:00", "published_display": "30 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Xeris Biopharma Holdings, Inc. (XERS) Stock Positioned for Long-Term Growth With Extended Keveyis Exclusivity?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNbG8xcGtFV2VaT0p6aEJaX3lyZlUxLVNLLWZWSjB0elE3ZE42b2FNWW1FWjFra1VjMDFOVmx2OS1QQnZGMTJQY01La2l1OXUxTXJWTTFscWp3cnlqQkVUb2diYVk5cHItT3c3ajR5SEhaRzhHTGhQWkdJb1lPb0dNRDV0cmFWcC1pV0NfLWVZQUNmVmprLUNfQTR3?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris reshapes its board as CEO John Shannon takes the chair", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQMl9Pb3VXRmNmVlpZelRUTW90RU9zV2ltQ2hocFJVNWtRY0RLbXFxWTRsdVgtX0Y5QmRYem9IRkZZSGtseEUwLWtGd2pHcXVlSTBhS3V1Mm1ILTV2WjFkcGt0ckQ1V2ZrSUxZYjJMaUVyaG9vXzB4dWw5ZmNMQUVPTWRGTW5WT1ZNX2VyQVBhTlRYSlR1Q1dhZTN3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jim Cramer Blesses a Caller\u2019s Speculative Investment in Xeris Biopharma", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPOU5wbzV1c2o4TnhtSTJvS1pCbDhxeV82bmNmUTBMSXpUTEtpZmFOODg4THR1VWRYaFp6cnVEU0h6bXZ2M2ZSTTFrYlRtNkRwRFN4ekpHSDVxU3phM3R3Z2h6bWQ4bUJ4ejVUUnRwbUNJOHFRSHVIaFh1Qmo2SEs3RTVaandrRGdfLTlycU9MWG8xTkFIaHc2dnJpbjA2WDg2Rmh5Vg?oc=5", "source_name": "Market source", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma Gets Notice of Allowance From US Patent and Trademark Office for New KEVEYIS Patent", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/xeris-biopharma-gets-notice-allowance-205130360.html", "source_name": "MT Newswires", "published_at": "2026-06-11T20:51:30+00:00", "published_display": "11 Jun 2026 20:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS\u00ae", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/xeris-biopharma-announces-notice-allowance-203900861.html", "source_name": "Business Wire", "published_at": "2026-06-11T20:39:00+00:00", "published_display": "11 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma to Retire $23 Million of Convertible Notes Through Private Exchange", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/xeris-biopharma-retire-23-million-121100161.html", "source_name": "MT Newswires", "published_at": "2026-06-11T12:11:00+00:00", "published_display": "11 Jun 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris receives patent allowance for Keveyis through 2039", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNRXBWMzVjNlhnXzRvZ0R5cmd6ZGhaR3BVaVVqZnlYVEtGUldLenVsd3BWSU41VmRqajZ4RU5WNkMtTVNyZndsenFlVF9wdzhkNnYwT015RzlCMUFFdDY4Q3I4NDdOS2lETFMzZW5aeFotYldJWHpyMFNvaFhYQlJlV0ZFZlczbEdqLXZCdTJQbjMtZXI5RHQtNnNaTEoyOHBJUEpacnN0VGlGYzEwZS1UQ1JhMA?oc=5", "source_name": "Investing.com", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma Announces Private Exchange of Convertible Notes", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQenhGdDBPSVNVSEVLX2ZheDFmQXZMZDd4VW9sLXVDU2Vkc2xSUlYxcGxuNHFNczNsUXoyMXUzbkVmOF80NzI1YkhrRk5ERnQzNXRDeUVIb0lhWFB0cloyWEVBUnVPc0pzM1NWWmlhaTEtMkYxM2xOY0xKMDVJM1JFcFZsRHBtV3NVamZWUDhUU1AyZFdtajFJUmhDVnpKYkx0Y0dOQVpkbG45Q3lITjhacDhBWjlHMmpnTTZ5TA?oc=5", "source_name": "Business Wire", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Looks Ridiculously Cheap If Growth Forecasts Are Even Halfway Right (NASDAQ:XERS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOMDdGbkItT1ZYeFBwVnk4UVVmaEJMUHdvd2FZWGMwRWtKRnNBYk01ZHZzTkRLSlFKVlRGbzkwTzZEcHhXTzBfMmlkU1pqTDVYUGwxZUdXZHBwaWc5SGtPc2pwSHRoSE5ZWnAwN3h2bXpscWRWMXR2NUJQaTBjX1dpTURfOHN1SUFaMXNlYnQ5MG42SjJPRmxvUG5jS0g3b3U2MzducXItYUF6TEJ2QzdDRFh3TjJ0SUliUGZlVQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hikma Pharmaceuticals PLC stock (GB00B128J450): Dividend hike and $250M buyback", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNX2ZfWkxLZDAyQUZNRU55RXhPVHI4dlZrTVVuc3RlV01XV0Jqd21vSDdYU0l3QkJOejBicXhjRXhQcmpkZHlVQ3BsRFE5ZFFxbFV3MWgtLUpndEZKTm1vbTAwaGlYMHEzWVVjNDVUYjFpM1hJS0NRTjdCc3pOeG9VNlg0QThScXpuV3lYNi0xY2NXMnkwdkFMYU8xYWU0WTIyaVdESzRVV2wxaThRazh6bTZCV1RPMWpJWW0tZy1qQUJVNjh6?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma Holdings, Inc. ($XERS) CEO 2025 Pay Revealed", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQRG9FQV9YMm9SYWxkVVBRTURYTHduWkZPd1BOODBJUEhyc1hkX0p6ZWJUaDdtRXBFcjFkdDRvSXRtR0lMaUlubUQ2N1g2MUhhQUxxLWJnVWRPRDJpZklUWXMxT3pQd0lFX2tkeFIwbWo4R3N2QVUzSWZxcXJXbkVFTi1sOEpScEFMbzY2UHozbTZtTzJUNWxPRWJnT3BDYUk2V25v?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma (XERS) Reports Q4 Earnings: What Key Metrics Have to Say", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxNcFlPckRubXFjR0hySHJwMzFUd0Zuc29kbEZyeUZPYmlhTlJsSkNPeHU2V3kxUTd6SzZaYk0zd3RqaWpXREJoOG54eVhnRUtwY0xUTEtuakQ5cktUVC13R3FOaEx1UGwzN2ZON3NkOEEtYkM5VzVmekVGNnlSejFMOWlocw?oc=5", "source_name": "Market source", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma director Shannon sells $176k in shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQMWNlOVpqTjM4UkpaOXgwVUllQ3BCWU9ETkJ4V1Y2UzNFclFiSFUzbFVfazZVcVVsNUJHUUV1bUM4RUt2b05hRnJ5U1pnblpDTFRGQnZvUEE0NmRGUFFlbXRzMDZ2NTJmdHp0bG12ZUdhRWFuVGdlV2VZallsT0w4MXdzZENpeFd4NlFsMTlraHRFX1dQN0RMM0RGa1F2ZGtpU19uNVpjNFRseVRkdmM4WFZ4MllNRmJia0E?oc=5", "source_name": "Investing.com", "published_at": "2026-01-06T08:00:00+00:00", "published_display": "06 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma Holdings Inc (XERS) News, Articles, Events & Latest Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTFB2ZW9wRWczVTF3MTVvczhHYnFrb2RZUDJEX2lhRmhlSUJodG9KX1pfeHNIWEd4TWFnaVFTRUhJUmNXU0ExTEczTkRqeHZvdS1f?oc=5", "source_name": "Stocktwits", "published_at": "2023-04-03T17:30:18+00:00", "published_display": "03 Apr 2023 17:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQeVg2eDhGd2hacmVFS0xXRVNKcUlqTFR3TXVjelU2LXJxVEFDQzJtMFJPUUs2bGJGa0V4S2thbEpaTVduVlRvNE9BbTFVZTVCVkZTLVdzRUZmaFd3QXhKT2VXT2JMSWZoSFNadWdFdHJWaldJRnZkOXNSUWlNbnA4T19IOWxPR0RUckVIZjByYkR6YnJoQ2lwUTdmQXZEYjF4WkRpbUJDWU9IenZFdEhMYlBxeXB2YXUxM0dObWdLNzVDY1lu?oc=5", "source_name": "Business Wire", "published_at": "2021-10-05T07:00:00+00:00", "published_display": "05 Oct 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwJBVV95cUxPS05zRzZNVWx5RFppWE53TFl4aUZUZWdaZF9VMGlEV3NldWJoV1V4VUN4MmZJZmJIUEtRckJBeHJQUE5jdmJ2Ulk4eG9kZERkbk9IUUppck9FZHlPejBJOFpVaXlVNVNIb3V1NmJINk14cTNTOWJpREw1elhxZFAyY29aT01fbXk1ZE14X2lJZ0RaSVBYQUR1Z2xFbVFraTBNX2NPZmRicDU4blQzbnFJTFZ1YW85eFBYektqbnJjNEEtTlFFNy1LRE8xNDhzZlpRVVVpNnllNmhpRHBUaGNtVkdMdERjUzczb2FGTnZpM0xsOGppTlRvVUJYbjB3MktScU5rSkYtenlzTXVmX09SNThTOVJwYTlmT3l0T1V6dm13VjF5dDlYMzNhcmlFODEzOUpvWVdCX0pGYm8?oc=5", "source_name": "Business Wire", "published_at": "2021-05-24T07:00:00+00:00", "published_display": "24 May 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Pharmaceuticals (XERS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiT0FVX3lxTFB6clc5Q2tzdFFKRXhQaW9RaDc5NTdnR2g0VzBGNlIwZ0UxSkU2RmF2WVRISEtCVlBMNFpLSE9ueWRYQmhpVUNPaExhWXBUQjg?oc=5", "source_name": "Zacks Investment Research", "published_at": "2018-06-27T10:13:02+00:00", "published_display": "27 Jun 2018 10:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XERS Stock Price and Chart \u2014 NASDAQ:XERS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5wRU55QUVTZlVZTGE0TmtLQXB2dkh5SUNDVE55T0FwbmJ3N3lLQVhhTGJma3I4MmRreHNONHVTZnJ1NGpJYUtRcjdUYncyRGxSS05ScjlaV3B4d0VP?oc=5", "source_name": "TradingView", "published_at": "2018-06-21T02:45:31+00:00", "published_display": "21 Jun 2018 02:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Enterprise value to revenue forward of Xeris Biopharma Holdings, Inc. \u2013 NASDAQ:XERS", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNNUZYWExTSkRocHUwSFpQbHpYVXFOSzNwM0lPWkZzcEdxUEpYYW9UQlN5SWRHbHZQYWZGVXdrQUxNWVg4M1lBcG1tX0plRFlhT0kxSkZGNmJOUlZFaVRjMmo5MjZkajJoQWtSRlluaTR5Z3pZNTdHQ2NKcnh5NGpLRldvWndldU5GeVFFajdZWklQR1diM3czMHR6VWl6YWlSWHY4VnltenNHNFlT?oc=5", "source_name": "TradingView", "published_at": "2026-07-10T12:39:28+00:00", "published_display": "10 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma (XERS) Moves 6.8% Higher: Will This Strength Last?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPMG9rc0hLS0RtQUxQaGVDRHJqeUdnZ1kybXlkMXk2dmFILW5TVzJmWUxvOF8tZ3ZKTFFFMC1yRzJjYUhNRlA2Z3VGNjNMcm5GSkd0T3A2M2o0VnlmS2ZlTHFuUy1oSS0yRm5qSW5RZUpSUHJtTmJldnIzOW42ZVR3dWFfNlFyeE5KaHg2YThLYnM3SEhuRVNwbA?oc=5", "source_name": "Market source", "published_at": "2026-07-08T14:37:00+00:00", "published_display": "08 Jul 2026 14:37", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma CFO Steven Pieper sells $383,176 in company stock", "summary": "Xeris Biopharma's CFO, Steven Pieper, sold 45,000 shares of company stock for approximately $383,176 in early July through a pre-arranged trading plan. This sale occurred after the stock delivered a 78% return over the past year, and InvestingPro data suggests the stock is curren", "url": "https://www.investing.com/news/insider-trading-news/xeris-biopharma-cfo-steven-pieper-sells-383176-in-company-stock-93CH-4780301", "source_name": "Investing.com", "published_at": "2026-07-08T11:11:28", "published_display": "08 Jul 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Xeris Biopharma Holdings, Inc. \u2013 NASDAQ:XERS", "summary": "The article focuses on the \"Price to earnings forward\" metric for Xeris Biopharma Holdings, Inc. (NASDAQ: XERS). It appears to be a financial data page from TradingView, providing an overview of the company's financials for investors and analysts interested in its valuation.", "url": "https://www.tradingview.com/symbols/NASDAQ-XERS/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-08T02:09:45", "published_display": "08 Jul 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma Holdings Insider Sold Shares Worth $383,176, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/xeris-biopharma-holdings-insider-sold-211904969.html", "source_name": "MT Newswires", "published_at": "2026-07-07T21:19:04+00:00", "published_display": "07 Jul 2026 21:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma CFO Steven Pieper sells $383,176 in company stock By Investing.com", "summary": "Steven Pieper, the CFO of Xeris Biopharma Holdings Inc. (NASDAQ:XERS), sold a total of 45,000 shares of company stock for approximately $383,176 in early July, under a pre-arranged trading plan. This sale follows a strong 78% return for the stock over the past year. After these t", "url": "https://ca.investing.com/news/stock-market-news/xeris-biopharma-cfo-steven-pieper-sells-383176-in-company-stock-93CH-4724053", "source_name": "Investing.com Canada", "published_at": "2026-07-07T21:41:51", "published_display": "07 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Xeris Pharmaceuticals Inc For: 7 July By Investing.com", "summary": "This article reports on a Form 4 filing for Xeris Pharmaceuticals Inc. on July 7, 2026. Form 4s are SEC filings used to report changes in beneficial ownership of a company's stock by insiders. The article indicates that Xeris Pharmaceuticals Inc. (XERS) stock was up 6.93% at the ", "url": "https://ca.investing.com/news/stock-market-news/form-4-xeris-pharmaceuticals-inc-for-7-july-93CH-4724061", "source_name": "Investing.com Canada", "published_at": "2026-07-07T21:41:51", "published_display": "07 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 XERIS BIOPHARMA HOLDINGS For: 7 July By Investing.com", "summary": "Investing.com reports the filing of Form 144 for Xeris Biopharma Holdings (XERS) on July 7. The article provides the company's stock performance and states that the information is \u00a9 Reuters. This brief notice is part of a larger financial news update.", "url": "https://ca.investing.com/news/stock-market-news/form-144-xeris-biopharma-holdings-for-7-july-93CH-4723968", "source_name": "Investing.com Canada", "published_at": "2026-07-07T20:41:51", "published_display": "07 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Steven Pieper sells 17,400 shares for $147,900 \u2014 XERS", "summary": "A recent SEC Form 144 filing indicates that Steven Pieper sold 17,400 shares of Xeris Biopharma Holdings, Inc. (XERS) common stock for a total of $147,900 on July 6, 2026. This transaction was executed under a 10b5-1 trading plan. The filing also notes prior issuer transactions f", "url": "https://www.stocktitan.net/sec-filings/XERS/144-xeris-biopharma-holdings-inc-sec-filing-bacc152115a4.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:41:51", "published_display": "07 Jul 2026 20:41", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma (XERS) officer sells 45,000 shares under Rule 10b5-1 plan", "summary": "Steven Pieper, an officer at Xeris Biopharma Holdings (XERS), sold 45,000 shares of common stock over two days, July 6-7, 2026, for a total of $383,176. These sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted in August 2025. After these transactions, Piep", "url": "https://www.stocktitan.net/sec-filings/XERS/form-4-xeris-biopharma-holdings-inc-insider-trading-activity-02ed52e75229.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:41:51", "published_display": "07 Jul 2026 20:41", "sentiment": "negative", "sentiment_pct": 32, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Xeris Biopharma Holdings, Inc. \u2013 NASDAQ:XERS", "summary": "This article provides financial data for Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), specifically focusing on its enterprise value to EBITDA forward metric. It appears to be a stub or data-focused page from TradingView, indicating that the market was closed at the time of acce", "url": "https://www.tradingview.com/symbols/NASDAQ-XERS/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T23:39:38", "published_display": "06 Jul 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider reports 400-share purchase and 17,000 RSUs | XERS SEC Filing - Form 144", "summary": "A recent SEC Form 144 filing for Xeris Biopharma Holdings, Inc. (XERS) reported insider transactions, including an open-market purchase of 400 common shares on May 17, 2017, and an issuance of 17,000 restricted stock units (RSUs) on December 28, 2017. The filing's header date is ", "url": "https://www.stocktitan.net/sec-filings/XERS/144-xeris-biopharma-holdings-inc-sec-filing-092e27d983d3.html", "source_name": "Stock Titan", "published_at": "2026-07-06T20:11:20", "published_display": "06 Jul 2026 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Xeris Biopharma Holdings, Inc. \u2013 NASDAQ:XERS", "summary": "This article provides financial data for Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), specifically focusing on its enterprise value to EBIT forward. It indicates market details such as \"Market closed\" and \"No trades,\" suggesting the data presented might be static or from a non-", "url": "https://www.tradingview.com/symbols/NASDAQ-XERS/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-06T17:11:20", "published_display": "06 Jul 2026 17:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Xeris Biopharma Holdings, Inc. \u2013 NASDAQ:XERS", "summary": "This article provides the \"Price to book forward\" for Xeris Biopharma Holdings, Inc. (NASDAQ: XERS). It is a financial data point displayed within the TradingView platform, showing the value and change percentage for a specific period. The content is primarily a presentation of t", "url": "https://www.tradingview.com/symbols/NASDAQ-XERS/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T20:09:55", "published_display": "05 Jul 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Xeris Biopharma (XERS) Is Up 7.7% After Governance, IP, And Balance Sheet Moves - And What's Next", "summary": "Xeris Biopharma (XERS) recently saw a 7.7% increase following several strategic moves including governance changes, intellectual property advancements, and balance sheet improvements. These actions, such as appointing a new Board Chair, securing a Keveyis patent extension until 2", "url": "https://www.sahmcapital.com/news/content/why-xeris-biopharma-xers-is-up-77-after-governance-ip-and-balance-sheet-moves-and-whats-next-2026-07-05", "source_name": "Sahm", "published_at": "2026-07-05T11:11:28", "published_display": "05 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Xeris Biopharma Holdings, Inc. \u2013 LSE:0A8E", "summary": "This article provides limited financial data for Xeris Biopharma Holdings, Inc. (LSE:0A8E), specifically its \"Price to book forward\" metric. The content primarily focuses on the company's financial overview within the TradingView platform and includes extensive navigation and cop", "url": "https://www.tradingview.com/symbols/LSE-0A8E/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-05T01:41:22", "published_display": "05 Jul 2026 01:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Xeris Biopharma Holdings, Inc. \u2013 NASDAQ:XERS", "summary": "This article provides financial information for Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), specifically focusing on its forward price to sales ratio. The content is presented within the TradingView platform, offering various market analysis tools and data provided by ICE Data", "url": "https://www.tradingview.com/symbols/NASDAQ-XERS/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T12:40:13", "published_display": "04 Jul 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Xeris Biopharma Holdings (XERS)", "summary": "This article analyzes the historical performance of investing $1,000 in Xeris Biopharma Holdings (XERS) over various periods, showing significant returns for investments made one and five years ago, but a loss for investments since its 2018 trading start. It details the company's", "url": "https://www.stocktitan.net/tools/stock-return-calculator/XERS", "source_name": "Stock Titan", "published_at": "2026-07-04T09:41:22", "published_display": "04 Jul 2026 09:41", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma Holdings (XERS) Patent Win Puts Its Valuation Back In Focus", "summary": "Xeris Biopharma Holdings (XERS) has garnered attention due to a patent win for its Keveyis product, potentially extending protection until 2039, and recent board and leadership changes. Despite being considered 25.7% undervalued at its current price of $8.28 against a fair value ", "url": "https://www.sahmcapital.com/news/content/xeris-biopharma-holdings-xers-patent-win-puts-its-valuation-back-in-focus-2026-07-03", "source_name": "Sahm", "published_at": "2026-07-03T10:10:26", "published_display": "03 Jul 2026 10:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)", "summary": "Xeris Biopharma Holdings, Inc. announced that its Compensation Committee granted non-qualified stock options and restricted stock units for an aggregate of 221,323 shares to 47 new employees. These inducement grants are made under Nasdaq Listing Rule 5635(c)(4) and are intended t", "url": "https://www.businesswire.com/news/home/20260702095916/en/CORRECTING-and-REPLACING-Xeris-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635C4", "source_name": "Business Wire", "published_at": "2026-07-03T02:41:24", "published_display": "03 Jul 2026 02:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Beth Hecht Sells 16,666 Shares of Xeris Biopharma Holdings Inc (XERS)", "summary": "Beth Hecht, an insider at Xeris Biopharma Holdings Inc (XERS), sold 16,666 shares of the company on July 1, 2026, bringing her total ownership to 1,161,128 shares. This sale contributes to a pattern of 24 insider sells and no buys over the past year. The stock, trading at $8.03, ", "url": "https://www.gurufocus.com/news/8943773/beth-hecht-sells-16666-shares-of-xeris-biopharma-holdings-inc-xers", "source_name": "GuruFocus", "published_at": "2026-07-02T23:41:24", "published_display": "02 Jul 2026 23:41", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Xeris Pharmaceuticals Inc For: 2 July By Investing.com", "summary": "The article reports on a Form 4 filing for Xeris Pharmaceuticals Inc. on July 2. Form 4 filings detail changes in beneficial ownership of company securities by insiders. The article also provides various financial market data and news headlines.", "url": "https://ca.investing.com/news/stock-market-news/form-4-xeris-pharmaceuticals-inc-for-2-july-93CH-4719284", "source_name": "Investing.com Canada", "published_at": "2026-07-02T22:41:24", "published_display": "02 Jul 2026 22:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma (XERS) director Nerissa Kreher listed as reporting person on Form 3", "summary": "Xeris Biopharma Holdings, Inc. director Nerissa Kreher has been listed as a reporting person on a recently filed Form 3. This initial statement of beneficial ownership indicates no reported buying, selling, acquiring, disposing, or other share transactions, with all transaction c", "url": "https://www.stocktitan.net/sec-filings/XERS/form-3-xeris-biopharma-holdings-inc-initial-statement-of-beneficial-o-0cbc35804beb.html", "source_name": "Stock Titan", "published_at": "2026-07-02T22:09:36", "published_display": "02 Jul 2026 22:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Xeris Biopharma (NASDAQ: XERS) receives stock and options grants", "summary": "Xeris Biopharma director Nerissa Kreher received equity-based compensation including 33,582 restricted stock units and stock options for 37,910 shares with an exercise price of $8.00. Both grants vest over three years, contingent on her continued service on the board. This Form 4", "url": "https://www.stocktitan.net/sec-filings/XERS/form-4-xeris-biopharma-holdings-inc-insider-trading-activity-3fef34ee64c4.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:41:24", "published_display": "02 Jul 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Planned sale: Xeris Biopharma (XERS) officer trades 16,666 shares", "summary": "Xeris Biopharma Holdings, Inc. officer Beth Hecht reported selling 16,666 shares of common stock at a weighted average price of $8.0319 per share. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 8, 2025. After the sale, Hecht retains ", "url": "https://www.stocktitan.net/sec-filings/XERS/form-4-xeris-biopharma-holdings-inc-insider-trading-activity-46469f0eb976.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:41:24", "published_display": "02 Jul 2026 21:41", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)", "summary": "Xeris Biopharma Holdings, Inc. announced that its Compensation Committee granted restricted stock units for 221,323 shares of common stock to 47 new employees on July 1, 2026. These grants were made under Xeris' Inducement Equity Plan, exclusively for new hires to incentivize emp", "url": "https://sg.finance.yahoo.com/news/xeris-announces-inducement-grants-under-200500769.html", "source_name": "Market source", "published_at": "2026-07-02T20:05:17", "published_display": "02 Jul 2026 20:05", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris gives 47 new hires 221,323 stock awards under Nasdaq rule", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxPM19iTDVucnh5b1dqSXhkS2dlMzRUSDFaRUlnd2Nqa0M2SHR1QXVqSTdVUmh3NGc5a2RZMnhTRUFkMEVhWHhfcmViMVBZV1k5TDhQdXdRemlHTS14MXNhQkVUQU9GdXNVaWFTeDNmR0JZQm9WZEpUVDJMemZRRmd2T2dZYXoxbFNzenA5a2xncHNPSkZvVXk3dGloSEJldWc4MFdTTTRGQ29WNU40a3hRSVQtdGVQX0haakJLMW5n?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma (XERS) officer sells 90,000 shares under 10b5-1 plan", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQUi00RGVaRGJKLU9QZ0RkMjBxYkdtSEFkd0t5RTE5SnE0TFctQ0lRZjhsRzBvQ1NQeWNfQnBzRENYanpUWGhDOUhCR05iQXFpS3FOLXFEREJQTE8zd014MHpRV1cwOXF1djA4YzJKcnktM2FpU3cxTGE3aVlVc2VFM25yWURBVjZyaTRuNG5wN1NHajV4QkQybWdtUXdLcmFaV2szQjZXaFh2UmtXSkYtSmlHd2g1UVNXSXpLWm1Dbw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Xeris Biopharma Holdings, Inc. SEC Filing", "summary": "This article reports on a Form 144 SEC filing by Xeris Biopharma Holdings, Inc. (XERS), indicating an intent to sell 120,000 shares of common stock with an aggregate market value of $950,400.00. The securities were acquired on January 29, 2024, as Restricted Stock Units from the ", "url": "https://www.stocktitan.net/sec-filings/XERS/144-xeris-biopharma-holdings-inc-sec-filing-27b9d312441a.html", "source_name": "Stock Titan", "published_at": "2026-07-01T20:41:17", "published_display": "01 Jul 2026 20:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XERS - Xeris Biopharma Holdings Inc Options", "summary": "This page provides an extensive overview of Xeris Biopharma Holdings Inc (XERS), including its last closing price, financial metrics, valuation ratios, and performance indicators. It also lists key statistics like market capitalization, income, sales, EPS, insider ownership, inst", "url": "https://finviz.com/stock?t=XERS&ty=oc&ta=0&p=d", "source_name": "Finviz", "published_at": "2026-07-01T12:39:24", "published_display": "01 Jul 2026 12:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma (NASDAQ: XERS) adds Nerissa Kreher and reshapes board", "summary": "Xeris Biopharma has announced significant changes to its Board of Directors, effective July 1, 2026. The company expanded its board from seven to eight members with the appointment of Dr. Nerissa Kreher as a Class III director. Additionally, CEO John Shannon has been named Chairp", "url": "https://www.stocktitan.net/sec-filings/XERS/8-k-xeris-biopharma-holdings-inc-reports-material-event-07d4a8f73da8.html", "source_name": "Stock Titan", "published_at": "2026-06-30T20:09:28", "published_display": "30 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris CEO picks up chairman role at fast-growing biopharma", "summary": "John Shannon, the CEO of Xeris Biopharma, has been appointed chairman of the company. This move sees him taking on an expanded leadership role at the fast-growing biopharma firm. The article, however, does not provide further details on the implications of this new appointment or", "url": "https://www.chicagobusiness.com/health-care/ccb-shannon-xeris-chairman-20260630/", "source_name": "Crain's Chicago Business", "published_at": "2026-06-30T17:40:25", "published_display": "30 Jun 2026 17:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma Holdings, Inc. Announces Board Changes, Effective July 1, 2026", "summary": "Xeris Biopharma Holdings, Inc. announced significant changes to its Board of Directors, effective July 1, 2026. John Shannon, the current Chief Executive Officer, will also assume the role of Chair of the Board, succeeding Marla Persky who remains as Lead Independent Director. Ad", "url": "https://www.marketscreener.com/news/xeris-biopharma-holdings-inc-announces-board-changes-effective-july-1-2026-ce7f5fdcdf89f02d", "source_name": "www.marketscreener.com", "published_at": "2026-06-30T13:40:25", "published_display": "30 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma Appoints CEO John Shannon Board Chair", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/xeris-biopharma-appoints-ceo-john-114842950.html", "source_name": "MT Newswires", "published_at": "2026-06-30T11:48:42+00:00", "published_display": "30 Jun 2026 11:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Announces Updates to Its Board of Directors", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/xeris-announces-updates-board-directors-110000958.html", "source_name": "Business Wire", "published_at": "2026-06-30T11:00:00+00:00", "published_display": "30 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Xeris Biopharma Holdings, Inc. (XERS) Stock Positioned for Long-Term Growth With Extended Keveyis Exclusivity?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNbG8xcGtFV2VaT0p6aEJaX3lyZlUxLVNLLWZWSjB0elE3ZE42b2FNWW1FWjFra1VjMDFOVmx2OS1QQnZGMTJQY01La2l1OXUxTXJWTTFscWp3cnlqQkVUb2diYVk5cHItT3c3ajR5SEhaRzhHTGhQWkdJb1lPb0dNRDV0cmFWcC1pV0NfLWVZQUNmVmprLUNfQTR3?oc=5", "source_name": "Market source", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris reshapes its board as CEO John Shannon takes the chair", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQMl9Pb3VXRmNmVlpZelRUTW90RU9zV2ltQ2hocFJVNWtRY0RLbXFxWTRsdVgtX0Y5QmRYem9IRkZZSGtseEUwLWtGd2pHcXVlSTBhS3V1Mm1ILTV2WjFkcGt0ckQ1V2ZrSUxZYjJMaUVyaG9vXzB4dWw5ZmNMQUVPTWRGTW5WT1ZNX2VyQVBhTlRYSlR1Q1dhZTN3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jim Cramer Blesses a Caller\u2019s Speculative Investment in Xeris Biopharma", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxPOU5wbzV1c2o4TnhtSTJvS1pCbDhxeV82bmNmUTBMSXpUTEtpZmFOODg4THR1VWRYaFp6cnVEU0h6bXZ2M2ZSTTFrYlRtNkRwRFN4ekpHSDVxU3phM3R3Z2h6bWQ4bUJ4ejVUUnRwbUNJOHFRSHVIaFh1Qmo2SEs3RTVaandrRGdfLTlycU9MWG8xTkFIaHc2dnJpbjA2WDg2Rmh5Vg?oc=5", "source_name": "Market source", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma Gets Notice of Allowance From US Patent and Trademark Office for New KEVEYIS Patent", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/xeris-biopharma-gets-notice-allowance-205130360.html", "source_name": "MT Newswires", "published_at": "2026-06-11T20:51:30+00:00", "published_display": "11 Jun 2026 20:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS\u00ae", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/xeris-biopharma-announces-notice-allowance-203900861.html", "source_name": "Business Wire", "published_at": "2026-06-11T20:39:00+00:00", "published_display": "11 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma to Retire $23 Million of Convertible Notes Through Private Exchange", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/xeris-biopharma-retire-23-million-121100161.html", "source_name": "MT Newswires", "published_at": "2026-06-11T12:11:00+00:00", "published_display": "11 Jun 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris receives patent allowance for Keveyis through 2039", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNRXBWMzVjNlhnXzRvZ0R5cmd6ZGhaR3BVaVVqZnlYVEtGUldLenVsd3BWSU41VmRqajZ4RU5WNkMtTVNyZndsenFlVF9wdzhkNnYwT015RzlCMUFFdDY4Q3I4NDdOS2lETFMzZW5aeFotYldJWHpyMFNvaFhYQlJlV0ZFZlczbEdqLXZCdTJQbjMtZXI5RHQtNnNaTEoyOHBJUEpacnN0VGlGYzEwZS1UQ1JhMA?oc=5", "source_name": "Investing.com", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma Announces Private Exchange of Convertible Notes", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQenhGdDBPSVNVSEVLX2ZheDFmQXZMZDd4VW9sLXVDU2Vkc2xSUlYxcGxuNHFNczNsUXoyMXUzbkVmOF80NzI1YkhrRk5ERnQzNXRDeUVIb0lhWFB0cloyWEVBUnVPc0pzM1NWWmlhaTEtMkYxM2xOY0xKMDVJM1JFcFZsRHBtV3NVamZWUDhUU1AyZFdtajFJUmhDVnpKYkx0Y0dOQVpkbG45Q3lITjhacDhBWjlHMmpnTTZ5TA?oc=5", "source_name": "Business Wire", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Looks Ridiculously Cheap If Growth Forecasts Are Even Halfway Right (NASDAQ:XERS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOMDdGbkItT1ZYeFBwVnk4UVVmaEJMUHdvd2FZWGMwRWtKRnNBYk01ZHZzTkRLSlFKVlRGbzkwTzZEcHhXTzBfMmlkU1pqTDVYUGwxZUdXZHBwaWc5SGtPc2pwSHRoSE5ZWnAwN3h2bXpscWRWMXR2NUJQaTBjX1dpTURfOHN1SUFaMXNlYnQ5MG42SjJPRmxvUG5jS0g3b3U2MzducXItYUF6TEJ2QzdDRFh3TjJ0SUliUGZlVQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hikma Pharmaceuticals PLC stock (GB00B128J450): Dividend hike and $250M buyback", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNX2ZfWkxLZDAyQUZNRU55RXhPVHI4dlZrTVVuc3RlV01XV0Jqd21vSDdYU0l3QkJOejBicXhjRXhQcmpkZHlVQ3BsRFE5ZFFxbFV3MWgtLUpndEZKTm1vbTAwaGlYMHEzWVVjNDVUYjFpM1hJS0NRTjdCc3pOeG9VNlg0QThScXpuV3lYNi0xY2NXMnkwdkFMYU8xYWU0WTIyaVdESzRVV2wxaThRazh6bTZCV1RPMWpJWW0tZy1qQUJVNjh6?oc=5", "source_name": "Ad Hoc News", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma Holdings, Inc. ($XERS) CEO 2025 Pay Revealed", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQRG9FQV9YMm9SYWxkVVBRTURYTHduWkZPd1BOODBJUEhyc1hkX0p6ZWJUaDdtRXBFcjFkdDRvSXRtR0lMaUlubUQ2N1g2MUhhQUxxLWJnVWRPRDJpZklUWXMxT3pQd0lFX2tkeFIwbWo4R3N2QVUzSWZxcXJXbkVFTi1sOEpScEFMbzY2UHozbTZtTzJUNWxPRWJnT3BDYUk2V25v?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma (XERS) Reports Q4 Earnings: What Key Metrics Have to Say", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwFBVV95cUxNcFlPckRubXFjR0hySHJwMzFUd0Zuc29kbEZyeUZPYmlhTlJsSkNPeHU2V3kxUTd6SzZaYk0zd3RqaWpXREJoOG54eVhnRUtwY0xUTEtuakQ5cktUVC13R3FOaEx1UGwzN2ZON3NkOEEtYkM5VzVmekVGNnlSejFMOWlocw?oc=5", "source_name": "Market source", "published_at": "2026-03-02T08:00:00+00:00", "published_display": "02 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma director Shannon sells $176k in shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQMWNlOVpqTjM4UkpaOXgwVUllQ3BCWU9ETkJ4V1Y2UzNFclFiSFUzbFVfazZVcVVsNUJHUUV1bUM4RUt2b05hRnJ5U1pnblpDTFRGQnZvUEE0NmRGUFFlbXRzMDZ2NTJmdHp0bG12ZUdhRWFuVGdlV2VZallsT0w4MXdzZENpeFd4NlFsMTlraHRFX1dQN0RMM0RGa1F2ZGtpU19uNVpjNFRseVRkdmM4WFZ4MllNRmJia0E?oc=5", "source_name": "Investing.com", "published_at": "2026-01-06T08:00:00+00:00", "published_display": "06 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Biopharma Holdings Inc (XERS) News, Articles, Events & Latest Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiUEFVX3lxTFB2ZW9wRWczVTF3MTVvczhHYnFrb2RZUDJEX2lhRmhlSUJodG9KX1pfeHNIWEd4TWFnaVFTRUhJUmNXU0ExTEczTkRqeHZvdS1f?oc=5", "source_name": "Stocktwits", "published_at": "2023-04-03T17:30:18+00:00", "published_display": "03 Apr 2023 17:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQeVg2eDhGd2hacmVFS0xXRVNKcUlqTFR3TXVjelU2LXJxVEFDQzJtMFJPUUs2bGJGa0V4S2thbEpaTVduVlRvNE9BbTFVZTVCVkZTLVdzRUZmaFd3QXhKT2VXT2JMSWZoSFNadWdFdHJWaldJRnZkOXNSUWlNbnA4T19IOWxPR0RUckVIZjByYkR6YnJoQ2lwUTdmQXZEYjF4WkRpbUJDWU9IenZFdEhMYlBxeXB2YXUxM0dObWdLNzVDY1lu?oc=5", "source_name": "Business Wire", "published_at": "2021-10-05T07:00:00+00:00", "published_display": "05 Oct 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Pharmaceuticals, Inc. to Acquire Strongbridge Biopharma plc in Stock and CVR Transaction, Creating an Innovative Leader in Endocrinology and Rare Diseases", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwJBVV95cUxPS05zRzZNVWx5RFppWE53TFl4aUZUZWdaZF9VMGlEV3NldWJoV1V4VUN4MmZJZmJIUEtRckJBeHJQUE5jdmJ2Ulk4eG9kZERkbk9IUUppck9FZHlPejBJOFpVaXlVNVNIb3V1NmJINk14cTNTOWJpREw1elhxZFAyY29aT01fbXk1ZE14X2lJZ0RaSVBYQUR1Z2xFbVFraTBNX2NPZmRicDU4blQzbnFJTFZ1YW85eFBYektqbnJjNEEtTlFFNy1LRE8xNDhzZlpRVVVpNnllNmhpRHBUaGNtVkdMdERjUzczb2FGTnZpM0xsOGppTlRvVUJYbjB3MktScU5rSkYtenlzTXVmX09SNThTOVJwYTlmT3l0T1V6dm13VjF5dDlYMzNhcmlFODEzOUpvWVdCX0pGYm8?oc=5", "source_name": "Business Wire", "published_at": "2021-05-24T07:00:00+00:00", "published_display": "24 May 2021 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xeris Pharmaceuticals (XERS)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiT0FVX3lxTFB6clc5Q2tzdFFKRXhQaW9RaDc5NTdnR2g0VzBGNlIwZ0UxSkU2RmF2WVRISEtCVlBMNFpLSE9ueWRYQmhpVUNPaExhWXBUQjg?oc=5", "source_name": "Zacks Investment Research", "published_at": "2018-06-27T10:13:02+00:00", "published_display": "27 Jun 2018 10:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XERS Stock Price and Chart \u2014 NASDAQ:XERS", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5wRU55QUVTZlVZTGE0TmtLQXB2dkh5SUNDVE55T0FwbmJ3N3lLQVhhTGJma3I4MmRreHNONHVTZnJ1NGpJYUtRcjdUYncyRGxSS05ScjlaV3B4d0VP?oc=5", "source_name": "TradingView", "published_at": "2018-06-21T02:45:31+00:00", "published_display": "21 Jun 2018 02:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 81, "total_relevant": 53, "sentiment_summary": {"positive": 9, "negative": 4, "neutral": 40, "score": 52, "total": 53, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 91, "events": [{"event": "general", "label": "Market update", "weight": 26.55, "count": 47}, {"event": "earnings", "label": "Earnings", "weight": 2.2, "count": 4}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 9, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 8.34, "latest_week": "2026-07-10", "one_week_move": 0.7, "four_week_move": 22.8, "twelve_week_move": 30.9, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 1.421824, "market_dynamics_buy_signal": false, "relative_strength": 1.863827, "fair_value_gap": 94.0, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 56.0725, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.7% over one week, +22.8% over four weeks, trend inactive, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 54, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 12}, {"label": "TradingView", "count": 8}, {"label": "Business Wire", "count": 6}, {"label": "Market source", "count": 5}, {"label": "MT Newswires", "count": 4}, {"label": "Investing.com Canada", "count": 4}, {"label": "Investing.com", "count": 3}, {"label": "Sahm", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 53}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 47}, {"label": "Earnings", "count": 4}, {"label": "Capital return", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "91/100 classification confidence."}, {"label": "Company focus", "value": "53", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+0.7% over one week, +22.8% over four weeks, trend inactive, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Enterprise value to revenue forward of Xeris Biopharma Holdings, Inc. \u2013 NASDAQ:XERS"}], "updated_at": "2026-07-16T11:44:02.149178+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}